Pre-clinical drug discovery, cell and molecular biology, protein purification

1. PARTHA PRATIM MITRA
27, Ancaster Road, Upper Kedron, QLD 4055, Australia.
Home: +61733510610 Cell: +61411292635, Email:mitpartha@gmail.com
Citizen: Australia.
Summary of Qualifications: A multi-skilled, highly energetic and productive professional with exceptional
organizational skills and hands-on experience. I have a superb track record of managing scientific research
projects, have extensive experience in biochemical assays, cell based assays, image-based assays, small
molecule screening, protein expression and purification using mammalian and bacterial system, molecular
biology, experiments on laboratory animals and a thorough knowledge of small molecule based drug discovery .
I am familiar with RNA-seq, NGS and CRISPR/Cas9 technologies. Major strengths include good
communication skills, excellent problem solving skills, competencies and strong team player, attention to detail,
respect for compliance in all regulated environments, meeting deadlines, and supervisory skills.
WORK HISTORY: Designation (09/2009-08/2016): Senior Research Officer, Cancer Biology, The University
of Queensland. Brisbane, QLD, Australia.
 Developed a therapeutic model where CDK9 inhibitors can be considered as a target for estrogen positive
breast cancer.
 Generated collaboration with big pharma company like Novartis, AstexPharma, LeSun Inc.
Senior Team Leader/ Principal Investigator, Cell Biology, Evolva Biotech., Basel, Switzerland,Hyderabad,
India(02/2007-08/2009):Project development: Principal Investigator of tuberculosis drug discovery program.
 Effectively pitched scientific ideas to the non-scientific team(Business Development team) at Evolva
 Liaising with international teams fromcountries of Denmark, Switzerland, Australia
 Contributed to building the patented Evolva platformtechnology
 Contributed to establishing and developing early drug discovery assays for various indications
 Contributed to writing proposals to various international organizations in the fields of anti-infectives and
neglected diseases.
 Assay Development: positive stranded RNA replication assay (Brome Mosiac Virus assay).
 Protein-Protein interaction: FRET assay for virus-host protein interaction.
Junior faculty member (03/2005 – 01/2007), Dept. of Cell Biology, University of Massachusetts Medical
School, Worcester, MA, USA.
 Identification of a novel function of p57/kip2 to regulate the histone H4 gene transcription
 Established a direct physical association between HiNF-P and p57/kip2.
 Development of HiNF-P knockout mouse.
 Successfully set up collaborations with other academic institutions and industry across the globe
Post-doctoral training (07/1997–02/2005), Dept. of Cell Biology, University of Massachusetts Medical Center,
Worcester, MA, USA.
 Biochemical purification and functional characterization of HiNF-P.
 Established HiNF-P a bifunctional regulator of histone H4 gene transcription.
EDUCATION
1997: Doctor of Philosophy (PhD) in Biochemistry. Jadavpur University, Calcutta, India.
AWARDS:
 Publication of month award from the University of Queensland, 2012.
 Best Poster. Nominated as one of the three best posters in the Drug Discovery Technology World
Conference, Boston, August,2004.
 Research Fellowship. Council of Scientific and Industrial Research (CSIR), India.
PATENT: US Patent: Patent Number(s): WO2004038008-A2 ; US2004142894-A1.
Description: Modulating cellular proliferation using a Histone Nuclear Factor P (HiNF-P) or Nuclear Protein or
Ataxia-Telangiectasia locus (NPAT) polypeptide, useful for diagnosing or treating cancer, immune disorders
and/or viral infections

2. PRESENTATION:
1.Breast Cancer Workshop,QIMR-TRI Brisbane, 2015.
2.Cancer Seminar Series, Translational Research Institute,Brisbane, 2014-15.
WORSHOP ATTENDED, 2016: Next Generation Sequencing (Agilent Technology) and ddPCR (Bio-Rad).
SELECTED PUBLICATIONS (in last five years) :
**Mitra P, et al. Targeting transcriptional regulation of MYB by CDK9 inhibitors selectively induce apoptosis
in ER+ve breast cancer. Oncotarget. Jan 24, 2016.
**Mitra P. Pathogenicity of Leishmania donovaniis associated with the high expression of a group low
molecular weight proteins.Tropical Parasitology, July,5(2) 2015.
**Mitra P. Tuberculosis: A Molecular Approach to Drug Discovery. Indian J. of Tuberculosis, Oct., 2012.
**Mitra P. et al. Estrogen Receptor-α Recruits P-TEFb to Overcome Transcriptional Pausing in Intron 1 of the
MYB Gene. Nucleic Acids Res. Jul;40(13):5988-6000.2012.
References: Available on request